Sun Pharmaceutical Industries received approval from the U.S. Food and Drug Administration for its supplemental Biologics License Application for ILUMYA. This regulatory green light allows the company to market the drug for the treatment of adults diagnosed with active psoriatic arthritis.
The U.S. Food and Drug Administration based its decision on results from the Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. These trials assessed the safety and efficacy of the medication in adult patients after two doses administered over 24 weeks. The company stated that no new safety signals appeared during these specific clinical evaluations. Safety data remained consistent with the established profile of the drug.
ILUMYA is an IL-23 inhibitor that first received approval from the regulator in 2018 for treating adults with moderate-to-severe plaque psoriasis. The company noted that the medication may increase the risk of infection. It advised that patients undergo evaluation for tuberculosis prior to starting the treatment regimen. Psoriatic arthritis affects approximately 2.4 million Americans, causing symptoms such as joint pain, stiffness, and swelling that can result in permanent damage.
Based on company and agency reports. For information only; not investment advice.